The brand’s Chief Brand Officer, Keke Palmer, talks starring in the new ad campaign, self-care practices, winning an NAACP ...
Ruxolitinib cream, a topical Janus kinase (JAK) 1/2 inhibitor, was initially approved by the FDA as a treatment for AD in September 2021. 1 This was based on data from the TRuE-AD (Topical ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results